Treatment of Microsatellite-Unstable Rectal Cancer in Sporadic and Hereditary Settings

DNA Mismatch Repair–deficient Rectal Cancer Is Frequently Associated With Lynch Syndrome and With Poor Response to Neoadjuvant Therapy

(2022) Lama F. Farchoukh et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

(2022) Julio Garcia-Aguilar et al.   JOURNAL OF CLINICAL ONCOLOGY

Microsatellite instability in rectal cancer: what does it mean? A study of two randomized trials and a systematic review of the literature

(2022) Marloes Swets et al.   HISTOPATHOLOGY

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

(2022) Andrea Cercek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence of Mismatch-Repair Deficiency in Rectal Adenocarcinomas

(2022) David J. Papke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer

(2021) Incheol Seo et al.   Journal for ImmunoTherapy of Cancer

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

(2021) Heinz-Josef Lenz et al.   JOURNAL OF CLINICAL ONCOLOGY

Synchronous Rectal Tumours with Different Molecular and Genetic Phenotypes Occurring in a Patient with Lynch Syndrome

(2021) Qiheng Gou et al.   Cancer Management and Research

Mismatch Repair Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy

(2020) Andrea Cercek et al.   CLINICAL CANCER RESEARCH

Risk of Metachronous Colorectal Neoplasm after a Segmental Colectomy in Lynch Syndrome Patients According to Mismatch Repair Gene Status

(2020) Felipe F. Quezada-Diaz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.

(2020) Satoshi Yuki et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial

(2020) John Burn et al.   LANCET

Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies

(2020) Monika Vyas et al.   Familial Cancer

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer

(2020) Anup Kasi et al.   JAMA Network Open

Multidisciplinary Conference and Clinical Management of Rectal Cancer

(2018) Georgios Karagkounis et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Does external beam radiation therapy to the pelvis portend worse ileal pouch outcomes? An international multi-institution collaborative study

(2018) A. L. Lightner et al.   Colorectal Disease

Microsatellite Instability (MSI) as an Independent Predictor of Pathologic Complete Response (PCR) in Locally Advanced Rectal Cancer

(2018) Shaakir Hasan et al.   ANNALS OF SURGERY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database

(2016) Pål Møller et al.   GUT

DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics

(2016) Nicole de Rosa et al.   JOURNAL OF CLINICAL ONCOLOGY

American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome

(2015) Joel H. Rubenstein et al.   GASTROENTEROLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Microsatellite Instability Detection by Next Generation Sequencing

(2014) S. J. Salipante et al.   CLINICAL CHEMISTRY

How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation?

(2014) Alex Vilkin et al.   HUMAN PATHOLOGY

Risk of Metachronous Colon Cancer Following Surgery for Rectal Cancer in Mismatch Repair Gene Mutation Carriers

(2013) Aung Ko Win et al.   ANNALS OF SURGICAL ONCOLOGY

BRAF mutation in sporadic colorectal cancer and Lynch syndrome

(2013) Alexandra Thiel et al.   VIRCHOWS ARCHIV

Risk of Colonic Neoplasia After Proctectomy for Rectal Cancer in Hereditary Nonpolyposis Colorectal Cancer

(2012) Matthew F. Kalady et al.   ANNALS OF SURGERY

First successful double-factor PGD for Lynch syndrome: monogenic analysis and comprehensive aneuploidy screening

(2012) G Daina et al.   CLINICAL GENETICS

Molecular pathways in colorectal cancer

(2012) Sam Al-Sohaily et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Correlation of tumour BRAF mutations andMLH1methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification

(2012) Michael T Parsons et al.   JOURNAL OF MEDICAL GENETICS

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

(2011) John Burn et al.   LANCET

Microsatellite instability and survival in rectal cancer

(2009) Wade S. Samowitz et al.   CANCER CAUSES & CONTROL

Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening

(2008) J. N. Poynter et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1

(2008) Marjolijn J L Ligtenberg et al.   NATURE GENETICS